A Peripheral Blood Diagnostic Test for Acute Rejection in Renal Transplantation

L. Li\textsuperscript{a,b,†}, P. Khatri\textsuperscript{a,†}, T. K. Sigdel\textsuperscript{a,b,†}, T. Tran\textsuperscript{a,b,}, L. Ying\textsuperscript{b}, M. J. Vitalone\textsuperscript{a,b,}, A. Chen\textsuperscript{b,}, S. Hsieh\textsuperscript{a,b,}, H. Dai\textsuperscript{a,b,}, M. Zhang\textsuperscript{b,}, M. Naensens\textsuperscript{b,}, V. Zarkhin\textsuperscript{b,}, P. Sansanwal\textsuperscript{a,}, R. Chen\textsuperscript{b,}, M. Mindrinos\textsuperscript{d,}, W. Xiao\textsuperscript{e,}, M. Benfield\textsuperscript{f,}, R. B. Ettenger\textsuperscript{g,}, V. Dharnidharka\textsuperscript{h,}, R. Mathias\textsuperscript{i,}, A. Portale\textsuperscript{j,}, R. McDonald\textsuperscript{k,}, W. Harmon\textsuperscript{l,}, D. Kershaw\textsuperscript{m,}, V. M. Vehaskari\textsuperscript{n}, E. Kamil\textsuperscript{o,}, H. J. Baluarte\textsuperscript{p,}, B. Warady\textsuperscript{i,}, R. Davis\textsuperscript{d,}, A. J. Butte\textsuperscript{b,}, O. Salvaterra\textsuperscript{h,} and M. M. Sarwal\textsuperscript{a,b,⁎,}

\textsuperscript{a}California Pacific Medical Center, Research Institute, San Francisco, CA
\textsuperscript{b}Department of Pediatrics, Stanford University, CA
\textsuperscript{c}Department of Surgery, Stanford University, CA
\textsuperscript{d}Department of Biochemistry, Stanford University, CA
\textsuperscript{e}Massachusetts General Hospital, Harvard Medical School, MA
\textsuperscript{f}Pediatric Nephrology, University of Alabama at Birmingham, AL
\textsuperscript{g}Division of Nephrology, Department of Pediatrics, David Geffen School of Medicine at UCLA, UCLA Children’s Health Center, University of California Los Angeles, CA
\textsuperscript{h}Department of Pediatrics Nephrology, University of Florida College of Medicine & Shands Children's Hospital, Gainesville, FL
\textsuperscript{i}Pediatric Nephrology, Nemours Children's Clinic Orlando, FL
\textsuperscript{j}Department of Pediatrics, University of California San Francisco, CA
\textsuperscript{k}Children’s Hospital & Regional Medical Center Seattle, WA
\textsuperscript{l}Department of Pediatrics, Harvard University, MA
\textsuperscript{m}Department of Pediatrics, University of Michigan, MI
\textsuperscript{n}Department of Pediatrics, University of Louisiana Health Sciences Center, LA
\textsuperscript{o}Cedars-Sinai Medical Center, Los Angeles, CA
\textsuperscript{p}The Children’s Hospital of Philadelphia, Philadelphia, PA
\textsuperscript{q}Children’s Mercy Hospital, Kansas City, MO
\textsuperscript{⁎}Corresponding author: Minnie Sarwal, sarwal@cpmcri.org
\textsuperscript{†}Equal contribution as first authors.

Monitoring of renal graft status through peripheral blood (PB) rather than invasive biopsy is important as it will lessen the risk of infection and other stresses, while reducing the costs of rejection diagnosis. Blood gene biomarker panels were discovered by microarrays at a single center and subsequently validated and cross-validated by QPCR in the NIH SNS01 randomized study from 12 US pediatric transplant programs. A total of 367 unique human PB samples, each paired with a graft biopsy for centralized, blinded phenotype classification, were analyzed (115 acute rejection (AR), 180 stable and 72 other causes of graft injury). Of the differentially expressed genes by microarray, Q-PCR analysis of a five gene-set (\textit{DUSP1, PBEF1, PSEN1, MAPK9 and NKR}) classified AR with high accuracy. A logistic regression model was built on independent training-set (n = 47) and validated on independent test-set (n = 198)samples, discriminating AR from STA with 91% sensitivity and 94% specificity and AR from all other non-AR phenotypes with 91% sensitivity and 90% specificity. The 5-gene set can diagnose AR potentially avoiding the need for invasive renal biopsy. These data support the conduct of a prospective study to validate the clinical predictive utility of this diagnostic tool.

Key words: Acute allograft rejection, biomarker, bioinformatics, renal allograft rejection, renal transplantation, transplantation genomics, transplant rejection, translational research

Abbreviations: AR, acute rejection; AZA, azathioprine; BKV, BK virus; CMV, cytomegalovirus; CSA, cyclosporine A; DSA, donor specific antibodies; EBV, Epstein-Barr virus; FDR, false discovery rate; FK, FK506; HCT, hematocrit; LRD, living related donors; MMF, mycophenolate mofetil; PBL, peripheral blood leukocytes; PB, peripheral blood; PAM, prediction analysis of microarrays; PRA, panel reactive antibody; Q-PCR, quantitative real time polymerase chain reaction; ROC, receiver operating characteristic; SAM, significance analysis of microarrays; STA, stable; WBC, White blood cell count.

Received 29 March 2012, revised 23 May 2012 and accepted for publication 12 June 2012

The accurate and timely diagnosis of acute renal allograft rejection (AR) is necessary to optimize immunosuppressive drug management and preserve renal function in kidney transplant recipients. Unfortunately, the methods of diagnosis remain imperfect. Since many conditions other than AR lead to renal allograft dysfunction, the diagnosis of AR cannot be made on functional grounds alone and requires confirmation using a kidney biopsy. Although, the diagnostic biopsy criteria for AR have been codified over
time (1), the diagnosis using biopsy process remains limited by sampling error, assessment variability, procedural morbidity and cost. Additionally, renal allograft dysfunction is a relatively insensitive means of detecting early AR; approximately 10% of patients with clinically normal renal function are found to have evidence of AR on surveillance biopsy (2). Ideally, a less-invasive means for diagnosing AR, could be used for surveillance of transplant recipients, thereby reducing the need for biopsy and providing a more efficient means of immune management of graft injury.

Transcriptional profiling studies on renal allograft biopsy specimens have demonstrated substantial, coordinated expression changes in many genes that uniquely identify patients with established AR, as well as other conditions in the differential diagnosis for allograft dysfunction (3–6). In general, these changes are related to the inflammatory infiltrate resident cells within the kidney, and associated transcriptional changes in renal tissue. However, when these studies have been applied to peripheral blood (PB) (7,8), the diagnostic changes related to AR have been less evident, presumably due to a reduced signal to noise ratio inherent in a site remote from the allograft (9).

In order to increase the sensitivity and specificity of detection for relatively rare biomarkers within molecularly heterogeneous samples such as PB, we employed a carefully designed methodological approach to integrate the transcriptional profiles of PB samples from patients with and without biopsy-proven AR from three different microarray platforms. Changes in PB transcriptional profiles were correlated with biopsy-proven AR, and used to distinguish AR from other common conditions arising in kidney transplant patients. The examination of changes across a highly regulated set of genes was used to assess their utility for the noninvasive diagnosis of AR and a diagnostic alternative to the invasive renal biopsy.

Methods

Patient and sample information

And 367 PB samples from 236 unique pediatric and young adult kidney transplant recipients were enrolled (as shown in Figure 1). Within this cohort, 137 patients were enrolled from Stanford University for discovery and validation, and 99 patients from the NIH/NIAID prospective study from 12 US transplant centers, “Suppressing the Immune System With or Without Steroids in Children Who Have Received Kidney Transplants” (SNS01; NCT00141037; ClinicalTrials.gov) were enrolled for independent external validation. Complete clinical data from the SNS study is discussed elsewhere in Sarwal et al. (10). The study was governed by IRB approval and informed consent.

Each PB sample in this study was paired with a contemporary renal allograft biopsy (within 48 hours) from the same patient. Surveillance biopsies were obtained from all patients at engraftment, 3, 6, 12 and 24 months post-transplantation and additionally at the times of suspected graft dysfunction (for SNS clinical study details see Sarwal et al. [10]; for SNS histology study details see Naesens et al. [11]). Multiple PB-biopsy pairs from the same patient were utilized as long as each biopsy had a conclusive phenotypic diagnosis. Each biopsy was scored by the center pathologist for each enrolling clinical site; but given the possibility of discordance in biopsy reads across centers, all biopsies were blindly rescored by a single central pathologist using to the Banff (12) classification (complete SNS histology data in Naesens et al. [11]). The PB-biopsy pairs were categorized as “acute rejection” (AR; n = 115), or as “stable” (STA, n = 180), if there was absence of AR and any other substantial pathology. A third category of PB-biopsy pairs were characterized as “non-AR/non-STA” (n = 72) if they exhibited no evidence of Banff graded AR, but either met the Banff criteria for “borderline” classification (n = 12), had a diagnosis of chronic allograft nephropathy (CAN; samples had IFTA grade ≥ 1; n = 37), or chronic calcineurin inhibitor toxicity (CNIT; n = 16), or bacterial/viral infection or other undefined chronic graft injury (n = 7).

Sample collection, RNA extraction, microarray hybridization and analysis

Blood was collected in 2.5 mL PAXgene™ Blood RNA Tubes (PreAnalytiX, Qiagen) or in Ficoll tubes for peripheral blood (PBL) isolation (the latter samples were only used for microarray discovery on Affymetrix). Total RNA was extracted using a previously published protocol(9). Our goal was to maximize the power of discovering a robust gene-set for AR, and to minimize platform specific artifacts (e.g., issues of cross-hybridization (13), specificity of hybridization (14), globin gene effect(5) of whole blood on the Affymetrix platform, differential stability of Cy dyes (15), platform specific bias). Furthermore, because each array platform uses different sets of genes that are represented by different probe set IDs, we used ALLUN (http://ailun.stanford.edu) to re-annotate the probe set IDs with the current Entrez Gene IDs. All Gene expression values were transformed to log2 for further analysis. We applied significance analysis of microarrays (SAM) (17) to identify differentially expressed genes for AR on all 3 platforms, with a threshold false discovery rate (FDR) < 5%.

Quantitative polymerase chain reaction (Q-PCR)

Standard protocols were used for Q-PCR reactions on the ABI 7900 Sequence Detection System (Applied Biosystems, Foster City, CA) under standard cycle conditions (10 min at 95°C, 40 cycles of 15s 95°C, 30 s at 60°C), using gene expression assays (Applied Biosystems, Foster City, CA). The relative amount of RNA expression was calculated using a comparative C(T) method. Expression values were normalized to 18S using ribosomal RNA endogenous reference and universal RNA (Agilent Inc., Santa Clara; Cat #740000).

Biological pathway and cell specific expression analysis

We used Ingenuity Pathway Analysis (IPA) to identify significant signaling pathways. We chose -log2[P > 1.3] as a threshold for identifying significant pathways in IPA. We used BioGPS (18,19) to identify the blood cell types in which the differentially expressed genes were highly expressed. A gene was highly expressed in a blood cell type if its expression in a given blood cell type was greater than 10 times its median expression over all tissues. We used hypergeometric test to determine whether the proportion of the highly expressed genes in each cell type was statistically significant or not. The p-values from hypergeometric test were corrected for multiple hypotheses using Benjamin–Hochberg correction.

Building a five-gene classification model for diagnosis of acute rejection

A schematic outline of the study is presented in Figure 1 and shows the number of samples used for discovery by microarrays (122 PB), verification by QPCR (34 PB), building an AR logistic regression model by penalized maximum likelihood method, in an independent sample set by QPCR (47 PB) and testing the performance of the model in the SNS clinical study (198).
Figure 1: Summary of Study Design. The gene-based biomarker discovery pipeline for an AR blood test follows a path of (a) discovery by microarrays across 3 different platforms across a defined set (n = 103) of AR and STA blood samples; followed by (b) verification (n = 34) and validation (n = 47) on independent AR and STA blood samples; and (c) prediction of AR (n = 198) in other varying phenotypes of graft injury likely to be encountered in an outpatient clinical setting. Array data generated from the three platforms were compared by mapping the transcripts to Entrez Gene identifiers. Common genes regulated significantly in AR on each platform were identified using a common significance threshold (SAM; FDR < 5%). A total of 122 microarrays were run on 103 unique samples. 19 samples were used for correlation of within sample data, across the three different platforms. A 32-gene set was selected for initial verification on 34 samples (Verification Set containing 17 AR and 17 STA) chosen from the samples used on the microarrays and a significant set of 5 genes (p < 0.05) were further validated in 47 independent samples from Stanford University for development of a 5-gene model by logistic regression analysis (Training Set containing 23 AR and 24 STA samples). This locked regression model generated using the 5 genes was applied to the second independent set of 198 samples (Test Set containing 32 AR, 94 STA and 72 nonAR/nonSTA clinical phenotypes) from SNS01, for accurate AR classification. Raw microarray data are available in NCBI GEO under Accession No. GSE14067.

PB). Summary statistics for patient demographic and clinical variables are provided in Table 1.

The 5-gene model was validated in a second independent cohort of 198 samples from SNS01 (Test Set). The Test Set consisted of blood samples collected at the time of biopsy confirmed AR (n = 32; [20]) with clinical graft dysfunction (greater than 10% increase from baseline serum creatinine values), and blood samples collected at the time of protocol biopsies with stable graft function (STA; n = 94). There was an additional phenotype of samples within the SNS01 sample set that was not used in the earlier process of single–center discovery and validation. These were PB collected at the time of biopsies where the diagnosis was not one of either Banff graded AR or one of normal renal histology; these samples were codified nonAR/nonSTA, and consisted of a collection of samples with different pathologies; n = 72. In this latter category, many samples had clinical graft dysfunction and the different pathological categories were based on the centralized biopsy read-outs (12 borderline AR, 37 CAN, 16 CNIT and 7 other pathology).

Evaluation for confounders
To examine if any demographic, clinical or immunosuppression confounders at baseline or at the time of sampling could have driven the segregation of the 5-gene set prediction score for AR, 18 different clinical confounders on the single-center samples were correlated with Q-PCR expression of each of the 5 genes in the single center data on 81 samples (34 Verification + 47 Training Set) using Pearson correlation. Additionally, we also performed univariate logistic regression for each clinical confounder with the risk of AR as well as a multivariate logistic regression model for a combination of all 18 clinical confounders and 5 genes’ expression values. The confounders were posttransplant time, recipient age, recipient gender, donor gender, donor source, donor age, steroid-free vs. steroid-based immunosuppression, total white blood cell count, hematocrit, CMV status, EBV status, BK virus infection, bacterial Infection, presence of donorspecific antibodies (DSA), panel reactive antibodies, use of induction therapy (either Daclizumab or T cell depleting antibodies), use of calcineurin inhibitors (tacrolimus or cyclosporine), and use of anti-metabolites (mycophenolate mofetil or azathioprine).

Results

Cross-platform microarray discovery for AR specific genes in peripheral blood
From 122 PB, we identified 2382 differentially expressed genes (false discovery rate; FDR < 5%). All of the
Table 1: Demographic information of PB samples for microarray experiments (n = 122) and PCR validation (n = 106)

<table>
<thead>
<tr>
<th></th>
<th>AR (n = 62)</th>
<th>STA (n = 62)</th>
<th>Non-AR (n = 168)</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical characteristics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender, % females</td>
<td>20.0%</td>
<td>20.9%</td>
<td>20.0%</td>
<td>1.00</td>
</tr>
<tr>
<td>Mean age, year</td>
<td>10.94 ± 6.01</td>
<td>10.31 ± 5.24</td>
<td>10.57 ± 5.69</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Immunosuppression, %SF</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA match</td>
<td>2.41 ± 1.41</td>
<td>2.24 ± 1.41</td>
<td>2.35 ± 1.41</td>
<td>0.67</td>
</tr>
<tr>
<td>Donor source, %LRD</td>
<td>44.64%</td>
<td>47.27%</td>
<td>52.00%</td>
<td>0.09</td>
</tr>
<tr>
<td><strong>Immunosuppression, %SF</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gender, % females</td>
<td>48.00%</td>
<td>44.64%</td>
<td>47.37%</td>
<td>0.09</td>
</tr>
<tr>
<td>Mean age, year</td>
<td>10.94 ± 6.01</td>
<td>10.31 ± 5.24</td>
<td>10.57 ± 5.69</td>
<td>0.05</td>
</tr>
<tr>
<td><strong>Immunosuppression, %SF</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HLA match</td>
<td>2.41 ± 1.41</td>
<td>2.24 ± 1.41</td>
<td>2.35 ± 1.41</td>
<td>0.67</td>
</tr>
<tr>
<td>Donor source, %LRD</td>
<td>44.64%</td>
<td>47.27%</td>
<td>52.00%</td>
<td>0.09</td>
</tr>
</tbody>
</table>

Verification of AR specific genes by Q-PCR

We chose 32 genes for QPCR verification (Figure 1A) that were differentially expressed in all microarray data sets, and were biologically relevant with enrichment of cell-specific immune responses in AR. These genes were DUSP1, IL1RAP, MCM7, NKTR, MAPK9, PSEN1, PT-PRC, SLPI, STAT1, STAT3, CFLAR, IL32, PBEF1, PHLDA1, IFNGR1, IL8RA, ITGAX, PLCG1, PTPN11, TNFAIP6, ZAP70, GOLGA8A, RYBP, TLRA, RNF130, F2RL1, GRZYB, PFN1, FCGR1A, NFATC3 and IL6R. Given the recent research on the dual role of FOXP3 in rejection (21,22) and tolerance (23,24), it was also selected for verification. 15 genes were significantly differentially expressed between AR and STA (p-value < 0.05). Out of these 15 genes, five genes (F2RL1, STAT1, FOXP3, PTPRC and IL6R; p < 0.05) have previously been shown to be involved in AR. Out of the remaining 10 genes, 8 genes were over-expressed in AR (DUSP1, MAPK9, NKTR, PBEF1, PSEN1, and RNF130, p = 0.0012; DUSP1, p = 0.0013; IFNGR1, p = 0.0062; ITGAX, p = 0.0011; PBEF1, p = 0.00008; PSEN1, p = 0.00007; RNF130, p = 0.0459; and RYBP, p = 0.0012), and 2 genes were under-expressed in AR (MAPK9, p = 0.0006; NFATC3 and IL6R, p = 0.0016).

Identification of the minimal discriminative gene set for AR

We applied logistic regression with best subset selection to the Verification Set in order to find the minimum number of genes necessary for the proper classification of biopsy-confirmed AR(25). Chi-square score for logistic regression models built using the 10 genes showed that in the data-set used, using five genes would have the same performance as a model using six or more genes. Additional selection criteria were used such as biological relevance and model performance (high statistical significance 10 p-value < 0.005 and low standard error of mean [SEM]), resulting in DUSP1, MAPK9, NKTR, PBEF1, and PSEN1.

Independent validation of the 5 genes in the single-center training set and building the 5 gene diagnostic model for AR

Expression of each of the five genes in an independent Training set of 47 Stanford samples (23 AR, 24 STA) was also significantly different (p-value < 0.05) (Figure 2A). This data was used to develop a logistic regression model with a
Figure 2: Single-center Verification and Validation of Gene Expression for the 5-Gene Set. Box plots of the QPCR gene expression values are shown for the selected 5 genes: DUSP1, PBEF1 And PSEN1 are upregulated in AR (red outline); NKTR and MAPK9 are downregulated in AR (green outline) in the single center Verification Set (n = 34; part A) and in the single center independent Training Set 1 (n = 47; part B), for building the logistic regression model on the 5 gene-set. We applied logistic regression with best subset selection to the Verification Set in order to find the minimum number of genes necessary for the proper classification of biopsy-confirmed AR. Chi-square score for logistic regression models built using these 10 genes showed that increase in the score was minimal when more than five genes were used in the model. Chi-square score for logistic regression models built using all 10 genes showed that the increase in Chi-square score from a model with 1 gene to 3 genes is 7.70; from a model with 3 genes to 5 genes is 1.87; and from a model with 5 genes to a model with 6 is only an increase of 0.48. Hence, the logistic regression model using a set of 5 genes was selected based on the best performing 5-genes set (Chi-square score = 29.63) as DUSP1, PBEF1, PSEN1, MAPK9, and NKTR. The p values for comparison of gene expression data for each gene are shown in each dataset and each value is significant (p < 0.05).

Evaluation for confounders
To examine if any demographic, clinical or immunosuppression confounders at baseline or at the time of sampling could have driven the segregation of the 5-gene set prediction score for AR, 18 different clinical confounders on the single-center samples were correlated with Q-PCR expression of each of the 5 genes in the Training set of 47 samples (23 AR, 24 STA) using Pearson correlation. Univariate logistic regression was also done for each clinical confounder with the risk of AR as well as a multivariate logistic regression model for a combination of all 18 clinical confounders and 5 genes’ expression values. By t-test, all 5 genes had significant change in expression only with the presence of donor specific antibody (DSA; p < 0.05). By univariate logistic regression model, all 5 genes were significantly associated with AR (p < 0.0001; AUC from 0.829-0.938) and DSA positivity (p < 0.0001; AUC = 0.828) while there was no association with the histology grade or C4d positivity (p = 0.80 for Banff score; p = 0.79 for C4d positivity). These data thus underscore that the coordinated expression of the 5-gene set in PB can diagnose AR with high confidence, irrespective of the differences in patient characteristics, immunosuppression and rejection timing.

Independent validation of the 5-gene model in the multi-center SNSO1 sample set
The 5-gene model was validated in a second independent cohort of 198 samples (Test Set) collected in 12 different centers as part of the SNSO1 study (Figure 2B). The test set consisted of PB-biopsy pairs with AR, STA, and an additional phenotype of samples within the SNSO1 sample set that was not used in the earlier process of single-center discovery and validation. These PB samples were collected at the time of biopsies where the diagnosis was not one of either Banff graded AR or one of normal renal histology; these samples were codified nonAR/nonSTA, and consisted of a collection of samples with different pathologies; n = 72; 12 borderline AR, 37 CAN, 16 CNIT and 7 other pathology.
Blood Gene Markers for Acute Rejection

Figure 3: Multi-Center Validation of the QPCR Prediction Probability for AR by the 5-Gene Set. A dot plot is shown for individual percent probability prediction score for AR on 198 independent samples over the course of the 3 year follow-up (time posttransplant in months on the X-axis) in the SNSO1 multicenter study. Each blood sample is paired with a biopsy for blinded, centralized, histological diagnosis of the phenotype. Based on the Receiver Operating Characteristic (ROC) curve for the logistic regression model across DUSP1, PBEF1, PSEN1, MAPK9, and NKTR, a cutoff of \( \theta = 0.52 \) was selected to have the best sensitivity and specificity to discriminate between AR and STA. In other words, the prediction probability has been derived from the logistic regression model across the 5 genes (Y-axis) and percent probability prediction score of \( > 52\% \) predicts the sample to have an AR phenotype. In part (A) the 32 AR samples are shown by red dots, with 3 misclassifications (91\% accuracy within class); the 94 STA samples are shown by green dots with 6 misclassifications (92\% accuracy). The ROC curve for AR vs. STA class is shown in part (B). In part (C) the 72 nonAR/nonSTA samples are shown, divided into 4 categories: 12 AR borderline (pink dots), 37 CAN (light blue dots), 16 CNIT (cyan dots) and 7 other diagnoses such as reflux nephropathy (\( n = 2 \)), BK nephropathy (\( n = 1 \)), FSGS recurrence (\( n = 1 \)) (dark blue dots) and ischemia (\( n = 3 \)). Within the AR borderline class 4 samples have \(<50\% \) prediction scores for AR and misclassify, giving the within class accuracy of 67\% (8/12 samples) for borderline AR. The ROC curve for AR vs. nonAR/nonSTA class is shown in part (D).

The accuracy of the 5-gene model was assessed by evaluating the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) on the AR and STA samples, as well as the AR and non-AR in the Test Set (Figure 3A). The 5-gene model has 91\% sensitivity, 94\% specificity, 83\% PPV, 97\% NPV and 92\% accuracy, to separate AR from STA samples (AUC 0.955; Figure 3B); and 91\% sensitivity, 90\% specificity, and 90\% accuracy to separate AR samples from all other phenotypes (STA and non-AR/non-STA; Figure 3C; AUC 0.937, Figure 3D). It is important to note that 8/12 of samples from patients classified as borderline rejection on biopsy were classified as AR by the 5-gene model (these have been classified as true negatives in the non-AR/non-STA cohort, but it can be argued that these samples could also be true positives). The high prediction of an AR phenotype in the borderline AR
samples suggests that preclinical injury in AR may also be identified by Q-PCR analysis of a PB sample and suggest earlier treatment for the patient.

**Discussion**

In the current study, we used a cross-platform, high-throughput, transcript profiling approach to identify a highly specific, biologically meaningful, concise gene set in PB whose expression correlates well with the AR/no AR status of contemporaneous biopsies collected from the same patients. A logistic regression model built on a set of 5 genes in PB and extensively validated by Q-PCR, accurately diagnosed rejection, with 91% sensitivity and 90% specificity, substantially improving on any current available method for specifically diagnosing AR. Importantly, though the 5-gene test was developed for a binary comparison of AR and STA samples, it was validated in an independent cohort that comprised of samples obtained at 12 different transplant centers, in patients with varying demographics and across multiple clinical phenotypes, such as CAN, CNIT, infection, and acute tubular necrosis, sub-clinical AR, clinical AR and STA. As the model was built using samples from a single center, and was validated in an independent multicenter cohort, general applicability of this test in real-world appears feasible where the patient population will contain heterogeneous graft conditions along the continuum from stable to AR.

The SNS01 trial arbitrarily assigned borderline AR in the nonAR/nonSTA category, but in retrospect, this might not have been biologically accurate as most of the “miscalifications” were actually borderline AR, and their inclusion in the AR group would further enhance the PPV of the test. This suggests a longer biologic process than previously thought in immune changes leading to rejection. It would be important to evaluate serial samples from patients developing clinical AR episodes to examine if the 5-gene model was used to predict the set of AR and subclinical borderline AR biopsies in the SNS01 subjects. Early minimally invasive diagnosis of AR would be a significant advance over current practice standards that depend on biopsy for diagnosis and initiation of treatment. At present, by the time a clinical trigger is available to warrant doing a biopsy for rejection diagnosis, the rejection has evolved with its full humoral or cellular mechanisms. Having a clinical indication for the rejection episode, based on the high score on the 5-gene test, that is earlier than a rise in the serum creatinine, would be a significant advance for the management of patients, as it would result in the earlier diagnosis of rejection and provide an early trigger for performing an indicated biopsy, if warranted. Work is underway in our group to refine the performance of the larger gene-set for discriminating cellular from humoral rejection, clinically important for discriminating treatment for AR.

The excellent positive and negative predictive values of the 5-gene model suggest that a PB test based on these genes could be useful for screening patients for absence of AR. Given the excellent discrimination of this test, there is strong justification for a larger, more definitive follow-up study with a larger number of AR patients for study, to evaluate if a higher AR gene score translates into risk of more aggressive AR or humoral versus cellular AR. The strong negative predictive value of the model for diagnosing absence of AR opens the door for personalized therapy, where patients can be potentially screened serially by the 5-gene test, and in the absence of AR risk, have reduced follow-up, be candidates to avoid unnecessary protocol biopsies and, in the presence of graft dysfunction, be evaluated for alternative etiologies, such as infection, obstruction or toxicity.

The 5-gene blood test may also provide a new means to monitor for resolution of AR after treatment intensification. Additional samples will have to be evaluated from patients undergoing treatment of AR to examine if immunosuppression intensification causes a decrement of the 5-gene test prediction score, commensurate with histological resolution of the AR episode, perhaps guiding assessment of a patient’s response to therapy.

The PB genes most strongly associated with graft rejection, do not correlate with multiple demographic, clinical, treatment modality and bacterial/viral infection parameters. Although there is significant correlation with DSA positivity, our model predicts AR, irrespective of cellular or humoral AR. We are further analyzing our data to develop a blood gene-based model that can further distinguish humoral from cellular rejection. Even though this is a minimal set of 5 genes for AR classification, expanding out to other populations may require the inclusion of the 10 gene-set. The 5 genes are central to leukocyte trafficking and T/B cell activation, and are mostly expressed in by activated monocytes in the peripheral circulation, reflecting injury mechanisms relating to oxidative cellular stress responses (DUSP1), apoptosis (MAPK9), IL2 dependant activation of cytolytic genes (NKTR), increased cell adhesion via the e-cadherin/ catenin complex (PSEN1), and vascular smooth muscle injury (PBEF1). It is likely that these genes play a pivotal role in the mechanism of cytolysis and graft microvasculature injury from activated monocytes in graft rejection (28,29) The association of the gene profile of the selected genes in blood with DSA and peripheral trafficking of monocytes supports the growing recognition of DSA as a culprit in graft injury (30,31) and monocytes as primary culprits in graft dysfunction (32,33).
Serial performance of the 5-gene test proposed in the current study suggests a means to stratify patients as high or low risk for rejections, even in the presence of other histological injuries in the graft. It may be anticipated that the more frequent assessment of risk afforded by the minimally invasive nature of this assay will facilitate more prompt therapeutic management which may alter the course of rejection, providing a critical, and as yet unavailable, new dimension of immunosuppression customization for a transplant patient. However, a couple of caveats should be noted. The sample numbers in the discovery set are limited, but are offset by the power of validating the discovery in the SNSO1 multicenter study. As this study was performed in children and young adults, the nature of the rejection may be more aggressive due to either the size mismatch of adult-sized organ and infant recipient, or the higher rate of treatment nonadherence adolescent recipient, both of which could result in stronger immune response signal. Additionally, none of the pediatric patients in this study received induction with anti-CD52 depletion therapy or with co-stimulatory blockade. Therefore, the performance of the 5-genes model should be further studied for its potential to diagnose rejection in patients of all ages, in larger sample cohorts and in different immunosuppressive regimens. The empirical results of the diagnostic potential of the selected 5-gene panel in this study suggest potential clinical utility and support the future development of a prospective clinical trial in children and extension of this work in adult renal transplant recipients to confirm clinical application.

Acknowledgments

We deeply appreciate the participation of patients at Stanford University and the NIH funded multicenter randomized study of steroid-avoidance versus steroid-based immunosuppression (SNSO1). We also are indebted to the support with patient recruitment and sample collections from transplant patients in the SNSO1 multicenter study centers. We thank Nancy Bridges and Daniel Rotrosen from NIH/NIAID for their continuous support and advice on the SNSO1 study. We thank Nikki Williams for the support throughout the manuscript preparation. The authors are grateful to Dr. Neeraja Kambham from Stanford University for her centralized, blinded reads of graft pathology and to Dr. Allan Kirk from Emory University for his support and suggestions to make the manuscript more meaningful. We are thankful to David Ide, Michael Riggs, and Katja Poole in the validation phase of this project. Support from for this project was funded by NIH grants U01AI055795 (OS awarded within the Cooperative Clinical Trials in Pediatric Transplantation Consortium), R01AI061739 (MS), and ARRA funding 3U01 AI055795 (OS awarded within the Cooperative Clinical Trials in Pediatric Transplantation Consortium).

Disclosure

Dr. Sarwal receives consulting and lecture fees from Bristol Meyers Squibb, Genentech and Astellas and has equity/ownership stock in Organ-I; Dr. Butte receives consulting fees from Johnson & Johnson, Genstruct, Lilly and Tercica, lecture fees from Siemens and Lilly and equity ownership/stock from Genstruct and NuMedii; Dr. Davis has equity ownership/stock in Affymetrix and Organ-I. VRD has received consulting fees from Bristol–Myers–Squibb and honoraria from Genzyme and Alexion.

References


Supporting Information

The following additional supporting information may be found in the online version of this article:

Table S1. Patient Demographics for all PB samples included in the microarray and Q-PCR studies. P values for age and posttransplant time were calculated using the T test with unequal variance. Probabilities of steroid usage, gender and donor source were calculated using Chi-Square analysis.

Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.